*click HERE for an explanation of standardised wording to be used by Scottish Boards regarding decisions on medicines since May 2016 Link to Formulary

Medicine	Indication	NHS Board Decision*	DTC Supplement	Date
Fampridine 10mg prolonged-release tablet (Fampyra®) SMC 2253	For the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS [expanded disability status scale] 4-7). In double-blind phase III studies fampridine, compared with placebo, improved walking ability in adults with multiple sclerosis and walking impairment. This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower	Available in line with local guidance for prescribing	180	Sept 2020
Fampridine 10mg prolonged-release tablet (Fampyra®) SMC2107	For the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS [expanded disability status scale] 4-7).	Not available as not recommended for use in NHS Scotland	172	Dec 2018
Fampridine (Fampyra®) (789/12)	For the improvement of walking in adult patients with multiple sclerosis (MS) with walking disability (EDSS [expanded disability status scale] 4 to 7).	Not available as not recommended for use in NHS Scotland	117 158	May/Jun 2012 Dec 2016
Faricimab solution for injection (Vabysmo®) SMC2685	Treatment of adult patients with visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO). Faricimab offers an additional treatment choice in the therapeutic class of antineovascularisation agents.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for		

		alternative medicines.		
Faricimab 120mg/ml solution for injection (Vabysmo®) SMC2512	For the treatment of adult patients with neovascular (wet) age-related macular degeneration (namd). Faricimab offers an additional treatment choice in the therapeutic class of antineovascularisation agents for this indication.	Available in line with national guidance	192	Nov 22
Faricimab 120mg/ml solution for injection (Vabysmo®) SMC2499	For the treatment of adult patients with visual impairment due to diabetic macular oedema (DMO) SMC restriction: treatment of visual impairment due to DMO in adults with best corrected visual acuity (BCVA) of 75 Early Treatment Diabetic Retinopathy Study (ETDRS) letters or less at baseline.	Available in line with national guidance	191	Nov 2022
Febuxostat (Adenuric®) 1153/16	The prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumour Lysis Syndrome (TLS). Restriction: prevention of hyperurucaemia in adult patients at intermediate risk of TLS in whom allopurinol is either unsuitable or contraindicated, such as those intolerant of allopurinol or those on whom allopurinol is contraindicated e.g. patients with renal impairment.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines (Link to Formulary)	156	Sep 2016
Febuxostat (Adenuric®) (637/10)	Chronic hyperuricaemia	GPs may prescribe under the direction of Rheumatology	101 99	Dec 10/Jan 2011 Aug/Sep 2010
Fedratinib 100mg hard capsules (Inrebic®) SMC2462	For the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post	Available in line with national guidance		

	polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.			
fenfluramine oral solution (Fintepla®) SMC2723	treatment of seizures associated with Lennox-Gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older. SMC restriction: patients whose seizures have not been controlled after trying two or more anti-epileptic medicines. In a randomised, double-blind, phase III study, fenfluramine significantly reduced drop seizure frequency in patients (aged 2 to 35 years) with Lennox-Gastaut syndrome that was inadequately controlled by current anti-epileptic medicines, compared with placebo.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		
Fenfluramine oral solution (Fintepla®) SMC2569	for the treatment of seizures associated with Dravet syndrome as an add-on to other anti-epileptic medicines for patients 2 years of age and older.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	195	December 2023
Fentanyl citrate (Breakyl®) (947/13)	Treatment of breakthrough pain (BTP)	Not recommended	134	Jan/Feb 2014
Fentanyl nasal spray (PecFent®) (663/10)	Maintenance of breakthrough pain in adults receiving maintenance opioid therapy for chronic cancer pain	GPs may prescribe under the direction of Palliative Care or Oncology	102	Jan/Feb 2011
Fentanyl nasal spray (Instanyl®) (750/11)	Chronic cancer pain	Non-formulary - alternatives preferred	116 114 102	Apr/May 2012 Feb 2012 Jan/Feb 2011

			94 93	Dec 09/Jan 2010 Oct/Nov 2009
Fentanyl transdermal patches (Durogesic®) (24/02)	Chronic intractable pain	Restricted use	24	2003
Fentanyl 40 micrograms per dose transdermal system (Ionsys®) SMC 1207/16	Management of acute moderate to severe post-operative pain in adult patients	Not available as not recommended for use in NHS Scotland	159	Feb 2017
Fentanyl transdermal patches (Durogesic D Trans®)	Chronic intractable pain	Non-formulary	52	2005
Fentanyl 12mcg/hr patch (Durogesic D Trans®)	Non-malignant pain	Non-formulary	58	2006
Fentanyl buccal tablets (Effentora®)	Breakthrough pain (BTP) in adults using opioid therapy for chronic cancer pain	GPs may prescribe under the direction of Palliative Care or Oncology	102 86	Jan/Feb 2011 Jan 2009
Fentanyl sublingual tablets (Abstral®)	Breakthrough pain (BTP) in adults using opioid therapy for chronic cancer pain	Not recommended in Tayside	102 86	Jan/Feb 2011 Jan 2009
Fenticonazole (Ginoxin®) (691/11)	Vulvovaginal candidiasis	Not recommended	103	Feb/Mar 2011
Ferric carboxymaltose (Ferinject®) (463/08)	Treatment of iron deficiency	HOSPITAL ONLY Main users - Haematology, Renal & General Medicine	109 107 102 81	Sep 2011 July 2011 Jan/Feb 2011 July 2008

Ferric maltol 30mg hard capsules (Feraccru®) SMC2500	In adults for the treatment of iron deficiency. Ferric maltol failed to demonstrate non-inferiority to an intravenous (IV) iron preparation, but was superior to placebo for correction of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD).	Not available as not recommended for use in NHS Scotland		
Ferric maltol 30mg hard capsules (Feraccru®) SMC 1202/16	In adults for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD).	Not available as not recommended for use in NHS Scotland	159	Feb 2017
Ferumoxytol, 30mg/mL solution for injection (Rienso®) (833/13)	Intravenous treatment of iron deficiency anaemia in adult patients with chronic kidney disease.	Non-formulary - alternatives preferred	125	Mar/Apr 2013
Fesoterodine fumarate (Toviaz®) (480/08)	Treatment of the symptoms that may occur in patients with overactive bladder syndrome	Non-formulary	81	Jul 2008
Fezolinetant film-coated tablets (Veoza®) SMC2702	For the treatment of severe and moderately severe haemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors.	Not recommended for use in NHS Scotland		NYP
Fidaxomicin (Dificlir®) (791/12)	CDI/CDAD	GPs may prescribe under direction of ID/Micro Restricted to treatment of first recurrence of C.difficile	122 119	Dec 2012 Aug/Sep 2012
Filgotinib 100mg and 200mg film-coated tablets (Jyseleca®) SMC2475	For the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). Filgotinib may be used as monotherapy or in combination with methotrexate. SMC restriction: in adults with moderate disease (a disease activity score [DAS28] of 3.2 to 5.1) when intensive therapy with 2 or more conventional dmards has not controlled the disease well enough, in combination with methotrexate or as monotherapy when methotrexate is contraindicated.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	191	Nov 22

Filgotinib 100mg and 200mg film-coated tablets (Jyseleca®)	For the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. Filgotinib provides an additional treatment choice in the therapeutic class of janus kinase (JAK) inhibitors.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	189	May 2022
Filgotinib 100mg and 200mg film-coated tablets (Jyseleca®) SMC2365	Indication under review: filgotinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Filgotinib may be used as monotherapy or in combination with methotrexate (MTX). SMC restriction: in patients with severe disease (a disease activity score [DAS28] greater than 5.1) that has not responded to intensive therapy with a combination of conventional DMARDs and in patients with severe disease inadequately controlled by a TNF antagonist in whom rituximab is not appropriate. In two phase III studies, filgotinib compared with placebo (both in combination with methotrexate), significantly improved signs and symptoms of rheumatoid arthritis in patients with an inadequate response to conventional or biologic DMARDs. Filgotinib was non-inferior to a biologic DMARD in patients who had an inadequate response to methotrexate.	Available in line with local guidance for prescribing	187	Dec 2021
Filgrastim (Nivestim®) (671/11)	The reduction in the duration of neutropenia.	Non-formulary - alternatives preferred	116 103	Apr/May 2012 Feb/Mar 2011

Filgrastim (Zarzio®) (704/11)	See SMC summary advice	Non-formulary - alternatives preferred	116 107	Apr/May 2012 Jul 2011
Filgrastim (TevaGrastim®) (629/10)	See SMC summary advice	HOSPITAL ONLY	99	Aug/Sep 2010
Filgrastim (Ratiograstim®) (577/09)	See SMC summary advice	Pending OHMMG decision	93	Oct/Nov 2009
Finerenone 10mg and 20mg film-coated tablets (Kerendia®) SMC2486	For the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	191	Nov 2022
Fingolimod 0.25mg, 0.5mg hard capsules (Gilenya®) SMC2154	As a single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of patients aged 10 to <18 years: - Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy. or - Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by two or more disabling relapses in one year, and with one or more gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous MRI.	Available in line with national guidance. Hospital only - paediatric MS.	175	Aug 2019
Fingolimod (Gilenya®) (1038/15)	A single disease modifying therapy in highly active relapsing remitting multiple sclerosis (RRMS) for the following adult patient groups: - Patients with high disease activity despite treatment with at least one disease modifying therapy	Available in line with local guidance for prescribing	147	Apr 2015

Fingolimod 0.5mg hard capsules (Gilenya®) (992/14)	Modifying therapy in highly active relapsing remitting multiple sclerosis	Available in line with local guidance for prescribing	141	Sept/Oct 2014
Fingolimod (as hydrochloride), 0.5mg hard capsules (Gilenya®) (763/12)	As single disease modifying therapy in highly active relapsing remitting multiple sclerosis (RRMS) for identified adult patient groups: - as single disease modifying therapy in highly active relapsing remitting multiple sclerosis (RRMS) restricted to use in adult patients with high disease activity despite treatment with a beta-interferon.	Available in line with local guidance for prescribing	124 121 120 116	Feb 2013 Nov 2012 Oct 2012 Apr/May 2012
Flecainide acetate (Tambocor XL®) (521/08)	AV nodal reciprocating tachycardia arrhythmias	GPs may prescribe under the direction of a Cardiologist	85	Dec 2008
Fludarabine phosphate (Fludara® Oral)	B-cell chronic lymphocytic leukaemia (CLL)	HOSPITAL ONLY	63	2006
Fluocinolone acetonide 190 micrograms intravitreal implant (Iluvien®) SMC2260	Prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. In a double-blind, phase III study in patients with recurrent non-infectious uveitis affecting the posterior segment of the eye, fluocinolone acetonide intravitreal implant reduced the number of recurrences of uveitis compared with sham injection.	Available in line with local guidance	181	November 2020
Fluocinolone acetonide (Iluvien®) (864/13)	Vision impairment associated with chronic diabetic macular oedema	Non-formulary - absence of clinician demand	135 128	Feb/Mar 2014 June/July 2013
Fluorouracil (Actikerall®) (728/11)	Hyperkeratotic actinic keratosis (Grade I/II)	Formulary	111	Nov 2011
Fluticasone furoate, umeclidinium, vilanterol (as trifenatate) 92 micrograms/55	Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled	Available in line with national guidance	167	April 2018

micrograms/22 micrograms inhalation powder (Trelegy® Ellipta®) SMC No 1303/18	corticosteroid and a long-acting β2-agonist. SMC restriction: in patients with severe COPD (forced expiratory volume in one second [FEV1] <50% predicted normal).			
Fluticasone furoate/vilanterol (Relvar Ellipta®) (953/14)	Asthma in adults and adolescents aged 12 years and older	Non-formulary - alternatives preferred	139	June/July 2014
Fluticasone furoate/vilanterol (Relvar®) (953/14)	COPD	Formulary - 3rd line choice	136	Mar/Apr 2014
Fluticasone furoate nasal spray (Avamys®) (544/09)	Allergic rhinitis in adults	Formulary - 2nd line choice	97 88	Jun/Jul 2010 Apr 2009
Fluticasone propionate/formoterol fumarate metered dose inhaler 50 microgram/5 microgram (flutiform®) SMC2178	The regular treatment of asthma in children aged 5 to 12 years where the use of a combination product (an inhaled corticosteroid and a long-acting β2 agonist) is appropriate: • For patients not adequately controlled with inhaled corticosteroids and 'as required' inhaled short-acting β2 agonist. or • For patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.	Available in line with national guidance.	175	Aug 2019
Fluticasone propionate/ formoterol fumarate 50microgram/5microgram, 25microgram/5microgram pressurised inhalation, suspension (Flutiform k-haler®) SMC2016	For the regular treatment of asthma where the use of a combination product [an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA)] is appropriate: • For patients not adequately controlled with ICS as 'as required' inhaled short-acting β2-agonist or • For patients already adequately controlled on both ICS and a LABA	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	169	July 2018

Fluticasone propionate and fomoterol fumarate MDI (Flutiform®) (736/11)	Regular treatment of asthma where the use of a combination product is appropriate	Formulary	123 121	Jan 2013 Nov 2012
Fluticasone/salmeterol (Seretide Accuhaler®)	COPD		100 Further info 36 34	Oct/Nov 2010 2003
Fluticasone/salmeterol (Seretide 50 Evohaler®)	Asthma	Non-formulary	42	2004
Fluvastatin XL (Lescol®)	Secondary prevention after PCI		36	2004
Follitropin delta solution for injection in a pre-filled pen (Rekovelle®) SMC2670	Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle. SMC restriction: for use in normal responders (patients with an anti-Müllerian hormone level of >5.4 pmol/L) or high responders (patients with an anti-Müllerian hormone level of ≥25 pmol/L).	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	198 NYP	
Follitropin alfa 150 IU/lutropin alfa 75 IU for injection (Pergoveris®) (444/08)	Stimulation of follicular development in women with severe LH and FSH deficiency	HOSPITAL ONLY - (Assisted Conception Unit)	77	Mar 2008
Follitropin alfa 75 units, 150 units, 225 units, 300 units, 450 units pre-filled pen for subcutaneous injection (Bemfola®)(1025/15)	In adult women for: - anovulation (including polycystic ovarian syndrome) in women who have been unresponsive to treatment with clomiphene citrate. - stimulation of multi-follicular development in women undergoing superovulation for assisted reproductive technologies (ART) such as in vitro fertilisation (IVF), gamete	HOSPITAL ONLY - (Assisted Conception Unit) (Obstetrics & Gynaecology Specialist List)	146	Feb 2015

	intra-fallopian transfer and zygote intra-fallopian transfer. - in association with a luteinising hormone (LH) preparation for the stimulation of follicular development in women with severe LH and follicle-stimulating hormone (FSH) deficiency. In clinical trials these patients were defined by an endogenous serum LH level <1.2 units/L.			
Follitropin delta 12 micrograms, 36 micrograms and 72 micrograms solution for injection (Rekovelle®) SMC No. (1269/17)	Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies such as an in vitro fertilisation or intracytoplasmic sperm injection cycle.	Not available as not recommended for use in NHS Scotland	163	Sep 2017
Foslevodopa-foscarbidopa (Produodopa) AbbVie Ltd SMC2574	Treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	197	May/June 2024
Fondaparinux sodium solution (Arixtra®) (668/10)	Acute symptomatic spontaneous superficial-vein thrombosis	Not recommended	101	Dec 2010/Jan 2011
Fondaparinux (Arixtra®)	ST segment elevation myocardial infarction (STEMI)	HOSPITAL ONLY	85 (Update) 77	Dec 2008 Mar 2008
Fondaparinux (Arixtra®) (420/07)	Unstable angina or non-ST segment elevation myocardial infarction (NSTEMI)	HOSPITAL ONLY	85 75	Dec 2008 Dec 2007
Fondaparinux (Arixtra®)	VTE prophylaxis in high risk patients undergoing abdominal surgery	Not recommended	60	2006
Fondaparinux (Arixtra®)	VTE prevention in high risk medical patients	Not recommended	58	2006
Fondaparinux (Arixtra®)	Acute DVT/PE treatment	Not recommended	58	2006

Fondaparinux (Arixtra®)	Venous Thromboembolism	Not recommended	48 (Update) 22	2002
Formoterol fumarate dihydrate / glycopyrronium bromide / budesonide 5mcg/9mcg/160mcg pressurised inhalation, suspension (Trixeo® Aerosphere) SMC2321	Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist. SMC restriction: in patients with severe COPD (forced expiratory volume in one second [FEV1] less than 50% predicted normal). Formoterol fumarate dihydrate / glycopyrronium bromide / budesonide (Trixeo® Aerosphere) offers an additional treatment choice of long-acting beta2-agonist (LABA), long-acting muscarinic antagonist (LAMA) and inhaled corticosteroid (ICS) in a single inhaler.	Not routinely available as local clinical experts do not wish to add the medicine to the forulary at this time or there is a local preference for alternative medicines.	183	Awaiting Publication
Formoterol (Easyhaler®) (375/07)	Asthma/COPD	Formulary	69	June 2007
Formoterol (Atimos® Modulite®) inhaler (349/07)	Broncho-obstructive symptoms	Formulary	74	Nov 2007
Formoterol inhaler (Atimos® Modulite®)	Asthma	Formulary	55	2206
Fosamprenavir (Telzir®) (431/07)	HIV-1 in children over 6 years	HOSPITAL ONLY Non-formulary	92 75	Aug/Sept 2009 Dec 2007

Fosamprenavir (Telzir®)	HIV	HOSPITAL ONLY	52	2005
Fosaprepitant 150mg powder for solution for infusion (Ivemend) SMC2108 following an abbreviated submission	Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in paediatric patients aged 6 months to 17 years. Fosaprepitant is given as part of a combination therapy.	Availabile in line with national guidance	172	Dec 2018
Fosaprepitant dimeglumine (Ivemend®) (678/11)	Nausea and vomiting	HOSPITAL ONLY (Oncology & Haematology)	116 104 83	Apr/May 2012 Mar 2011 Oct 2008
Fosdenopterin powder for solution for injection (Nulibry®) SMC2624	For the treatment of patients with molybdenum cofactor deficiency (mocd) Type A	Available in line with national guidance		
Fosfomycin trometamol granules for oral solution (equivalent to 3g fosfomycin) (Monuril®) SMC 1163/16	Treatment of acute lower uncomplicated urinary tract infections, caused by pathogens sensitive to fosfomycin in adult and adolescent females. Prophylaxis in diagnostic and surgical transurethral procedures. Consideration should be given to national guidance on the appropriate use of antibacterial agents.	Available in line with National Guidance	157	Nov 2016
Fosfomycin (Fomicyt®) (1033/15)	For the treatment of the following infections in adults and children including neonates: - Acute osteomyelitis - Complicated urinary tract infections - Nosocomial lower respiratory tract infections - Bacterial meningitis - Bacteraemia that occurs in association with, or is suspected to	HOSPITAL ONLY - (Infectious Diseases/ Microbiology recommendation only) Alert antibiotic list Pending confirmation	146	Mar 2015

	be associated with, any of the infections listed above.			
Fostamatinib 100mg and 150mg film-coated tablets (Tavlesse®) SMC2300	Indication under review: treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments. SMC restriction: for the treatment of patients with severe symptomatic ITP or with a high risk of bleeding who have not had a suitable response to other therapies, including a thrombopoietin receptor-agonist (TPO-RA), or where use of a TPO-RA is not appropriate. Fostamatinib has been shown to be significantly more effective than placebo in raising and maintaining platelet counts at (or above) a minimum target level in previously-treated patients with ITP.	Available in line with local guidance for prescribing	183	March 2021
Fremanezumab 225mg solution for injection in pre-filled syringe (Ajovy®) SMC2226	For prophylaxis of migraine in adults who have at least four migraine days per month.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	179	Apr 2020
Frovatriptan (Migard®)	Migraine	Non-formulary	39 36 28	2004 2003
Fruquintinib hard capsule (Fruzaqla®) SMC2748	Treatment of adult patients with metastatic colorectal cancer (mcrc) who have been previously treated with available therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, with or without an anti-VEGF	Not available as not recommended for use in NHS Scotland		

	therapy, and if RAS wildtype and medically appropriate, an anti-EGFR therapy. Fruquintinib, compared with placebo, significantly improved overall survival in adults with mcrc who had been previously treated with available therapies.			
Fulvestrant (Faslodex®)	Advanced breast cancer	Non-formulary	112 105 150	Dec 2011 Apr/May 2011 2004
Fulvestrant, 250mg, solution for injection (Faslodex®) SMC No 114/04	For the treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-oestrogen therapy, or disease progression on therapy with an anti-oestrogen	Available in line with local guidance for prescribing	154	
Fulvestrant 250 mg solution for injection (Faslodex®) SMC No 1294/17	Treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy	Not available as not recommended for use in NHS Scotland	166	Feb 2018
futibatinib film-coated tablets (Lytgobi®) SMC2661	as monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. Futibatinib offers an additional treatment choice in the therapeutic class of fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors. Another FGFR tyrosine kinase inhibitor was accepted for use under the end of life and orphan process.			

Back to top Back to homepage